Skip to main content
All lobbying clients

PHARVARIS PHARMACEUTICALS, INC. (FKA PHARVARIS, INC.)

Lobbying client · Massachusetts · filed 2025 to 2026

Late-stage biopharmaceutical company

$160,000 Reported spend
8 Filings counted
1 Outside firm hired
1 Bill named

Spend is reported income plus in-house expenses across 8 filings. Everything on this page comes from one LDA client record (65771), filed by the registrant listed below. These filings have also been reported as PHARVARIS, INC.

 Who filed for this client 1

Spend per registrant: fees an outside firm reported, or the costs the client reported for lobbying in-house. The rows add up to the total above.

 Bills named in these filings 1
 Reported by year 2 years
  • 2026 $120,000 3 filings
  • 2025 $40,000 5 filings
 Issues lobbied 4

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

 Agencies and chambers lobbied 2
  • HOUSE OF REPRESENTATIVES 5
  • SENATE 5
 Foreign entities disclosed 2
  • PHARVARIS GMBH Switzerland named on 1 filing · highest disclosed ownership 100% · largest disclosed contribution $0
  • PHARVARIS N.V. Netherlands named on 1 filing · highest disclosed ownership 100% · largest disclosed contribution $0

Section 7 of the LD-2: a foreign company or government that owns part of the client, pays toward the lobbying, or benefits from it. Figures are the highest single disclosure across these filings, not a sum: the same stake is re-disclosed each quarter.

Filings through , the newest posted date on this record. Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.

Report a problem